Immunotherapy in sarcoma: A new frontier

Discovery Medicine

Volumn 17, Issue 94, 2014, Pages

  Wilky, Breelyn A ^a   Goldberg, John M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CELECOXIB; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUDARABINE; FREUND ADJUVANT; GANGLIOSIDE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERFERON; INTERLEUKIN 2; ISCOMATRIX; NY ESO 1 ANTIGEN; OPT 821; PEPTIDE; PEPTIDE VACCINE; PRAME ANTIGEN; RAPAMYCIN; RECOMBINANT ANTIGEN; RECOMBINANT ESO 1 ANTIGEN; RECOMBINANT INTERLEUKIN 7; RESIQUIMOD; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BIOCHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL TRANSFER; EWING SARCOMA; HUMAN; IMMUNE CHECKPOINT; IMMUNE RESPONSE; IMMUNITY; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; T LYMPHOCYTE; IMMUNOTHERAPY;

HUMANS; IMMUNOTHERAPY; SARCOMA;

EID: 84899073090     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg 14(3):199-220, 1891.
2. Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, Wang J, Gao W, Huang Q, Huang W, Zheng W, Xiao J. Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. Genet Test Mol Biomarkers 17(6):458-463, 2013.
3. Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys 82(2):924-932, 2012.
4. Goldberg J, Grier H, Fisher D, Dranoff H, Hodi FS. GM-CSF Secreting Autologous Tumor Vaccines for the Microphthalmia Transcription Factor Associated Tumors. An AACR Special Conference in Cancer Research, Tumor Immunology: New Perspectives; Miami, FL; Dec. 2-5, 2008. Poster session A. 2008.
5. Goorin AM, Delorey MJ, Lack EE, Gelber RD, Price K, Cassady JR, Levey R, Tapper D, Jaffe N, Link M, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2(5):425-431, 1984.
6. Jungbluth A, Busam K, Iversen K, Kolb D, Coplan K, Chen Y, Stockert E, Ladanyi M, Old L. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 94(2):252-256, 2012.
7. Kim J, Moon Y, Kwon K, Bae J, Wagle S, Kim K, Park H, Lee H, Moon W, Chung M, Kang M, Jang K. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLOS One 8(12):e82870, 2013.
8. Krishnadas D, Bao L, Bai F, Chencheri S, Lucas K. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumour Biol, epub ahead of print, Mar. 2, 2014.
9. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant P. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol 188(7):3080-3087, 2012.
10. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14(15):4850-4858, 2008.
11. Maki R, Jungbluth A, Gnjatic S, Schwartz G, D'adamo D, Keohan M, Wagner M, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old L, Gerd R. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013:ID168145, 2013.
12. Noguchi G, Ota J, Ishigaki H, Onuki T, Kato Y, Moriyama M. [A case of retroperitoneal angiosarcoma effectively treated with recombinant interleukin-2]. Nihon Hinyokika Gakkai Zasshi 103(6):697-703, 2012.
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252-264, 2012.
14. Peters H, Yan Y, Nordgren T, Cutucache C, Joshi S, Solheim J. Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biol Ther 14(8):752-760, 2013a.
15. Peters H, Yan Y, Solheim J. APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells. Oncoimmunology 2(10):e26293, 2013b.
16. Pollack S, Jungbluth A, Hoch B, Farrar E, Bleakley M, Schneider D, Loggers E, Rodler E, Eary J, Conrad ER, Jones R, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118(18):4564-4570, 2012a.
17. Pollack S, Li Y, Blaisdell M, Farrar E, Chou J, Hoch B, Loggers E, Rodler E, Eary J, Conrad ER, Jones R. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7(2):e32165, 2012b.
18. Ratnavelu K, Subramani B, Pullai C, Krishnan K, Sugadan S, Rao M, Veerakumarasivam A, Deng X, Hiroshi T. Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report. Oncol Lett 5(5):1457-1460, 2013.
19. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29(7):917-924, 2011.
20. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909-915, 2004.
21. Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'aglio C, D'ambrosio L, Pisacane A, Sarotto I, Miano S, Ferrero I, Carnevale-Schianca F, Pignochino Y, Sassi F, Bertotti A, Piacibello W, Fagioli F, Aglietta M, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res 74(1):119-129, 2014.
22. Simon-Keller K, Paschen A, Hombach A, Ströbel P, Coindre J, Eichmüller S, Vincent A, Gattenlöhner S, Hoppe F, Leuschner I, Stegmaier S, Koscielniak E, Leverkus M, Altieri D, Abken H, Marx A. Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells. Am J Pathol 182(6):2121-2131, 2013.
23. Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S, Kawano K, Kawahara A, Kage M, Ohshima K, Yamanaka R, Shichijo S, Shirouzu K, Itoh K, Sasada T. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci 104(10):1285-1294, 2013.
24. Weber J, Vogelzang N, Ernstoff M, Goodman O, Cranmer L, Marshall J, Miles S, Rosario D, Diamond D, Qiu Z, Obrocea M, Bot A. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 34(7):556-567, 2011.
25. Yu F, Miao J. Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors. Tumour Biol 34(6):3371-3375, 2013.
26. Zhang H, Maric I, Diprima M, Khan J, Orentas R, Kaplan R, Mackall C. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122(7):1105-1113, 2013.
27. Zhu S, Denman C, Cobanoglu Z, Kiany S, Lau C, Gottschalk S, Hughes D, Kleinerman E, Lee D. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res, epub ahead of print, Nov. 8, 2013.